Allison Greer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Allison Greer has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Andrew N. J. Tutt
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
1 shared publication - Anh Minh Tran Huynh
Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas
1 shared publication - Anran Chen
Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas
1 shared publication - Bora Lim
Department of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA
1 shared publication - Carolina Gutierrez
Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas
1 shared publication - Christina Sallas
Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF18
LIG1 Loss in TP53 -mutant Triple-Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP–ATR Inhibitor Combinations
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF18
Open AccessLIG1 Loss in TP53 -mutant Triple-Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP–ATR Inhibitor Combinations
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.